Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

651
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
651

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comments to the "Letter to the Editor" for the manuscript titled "Increased expression of inflammasome signaling genes and proteins in selective brain regions in the intermediate stage of Alzheimer's disease".

Brain pathology (Zurich, Switzerland)·2026
Same author

Electronic cigarette vapor exposure modifies stroke-induced transcriptional and microglial responses in a sex-dependent manner.

Neurochemistry international·2026
Same author

PRECISE TBI Model Catalog: Increasing Accessibility and Reproducibility in TBI research.

bioRxiv : the preprint server for biology·2026
Same author

Increased expression of inflammasome signaling genes and proteins in selective brain regions in the intermediate stage of Alzheimer's disease.

Brain pathology (Zurich, Switzerland)·2026
Same author

Traumatic Brain Injury and Endocytosis: Reduced Rodent Hippocampal Endocytosis Proteins and Human Clathrin Light Chain Polymorphisms Are Associated with Impaired Neurological Outcomes After TBI.

Molecular neurobiology·2026
Same author

Feasibility Study on Inflammasome Proteins as Biomarkers in the Cerebrospinal Fluid of Pediatric Patients with Hydrocephalus Due to Intraventricular Hemorrhage.

Biomolecules·2026

Related Experiment Video

Updated: Nov 30, 2025

Controlled Cortical Impact Model for Traumatic Brain Injury
05:30

Controlled Cortical Impact Model for Traumatic Brain Injury

Published on: August 5, 2014

29.3K

Glibenclamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.

Ruchira M Jha1,2, Stefania Mondello3, Helen M Bramlett4

  • 1Safar Center for Resuscitation Research, Department of Critical Care Medicine, Anesthesiology, and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Journal of Neurotrauma
|November 18, 2020
PubMed
Summary

Glibenclamide (GLY) improved motor function and reduced lesion size in rats with controlled cortical impact (CCI) traumatic brain injury (TBI). This suggests GLY may be a promising therapeutic for specific TBI types, aiding precision medicine development.

Keywords:
cerebral edemaconsortiumcontrolled cortical impactcontusionfluid percussion injuryglyburidepenetrating ballistic-like brain injuryratsulfonylurea receptor-1

More Related Videos

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
09:49

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Published on: January 20, 2023

3.5K
A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation
06:50

A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation

Published on: June 10, 2020

2.1K

Related Experiment Videos

Last Updated: Nov 30, 2025

Controlled Cortical Impact Model for Traumatic Brain Injury
05:30

Controlled Cortical Impact Model for Traumatic Brain Injury

Published on: August 5, 2014

29.3K
Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury
09:49

Assessing Changes in Synaptic Plasticity Using an Awake Closed-Head Injury Model of Mild Traumatic Brain Injury

Published on: January 20, 2023

3.5K
A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation
06:50

A Preclinical Controlled Cortical Impact Model for Traumatic Hemorrhage Contusion and Neuroinflammation

Published on: June 10, 2020

2.1K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Traumatic Brain Injury Research

Background:

  • Traumatic brain injury (TBI) is a significant cause of mortality and disability.
  • Developing effective pharmacological treatments for TBI remains a challenge.
  • Glibenclamide (GLY) has shown preclinical promise for TBI based on Operation Brain Trauma Therapy (OBTT) consortium findings.

Purpose of the Study:

  • To evaluate the efficacy of Glibenclamide (GLY) in multiple rat models of traumatic brain injury (TBI).
  • To assess GLY's impact on motor, cognitive, neuropathological, and biomarker outcomes across different TBI models.
  • To determine if GLY's therapeutic effects are model-dependent and to identify optimal TBI phenotypes for its application.

Main Methods:

  • Adult Sprague-Dawley rats were subjected to three TBI models: fluid percussion injury (FPI), controlled cortical impact (CCI), and penetrating ballistic-like brain injury (PBBI).
  • Animals received GLY treatment (loading dose followed by continuous infusion) or vehicle control.
  • Outcomes assessed included motor function (cylinder task, beam balance/walk), cognitive function (Morris water maze), lesion volume, and biomarker levels (GFAP, Uch-L1).

Main Results:

  • GLY significantly improved motor outcomes in both FPI and CCI models.
  • In the CCI model, GLY reduced 21-day lesion volume and showed positive neuropathological effects.
  • GLY did not benefit outcomes in the PBBI model and worsened cognitive performance in CCI rats on a specific latency test.

Conclusions:

  • Glibenclamide (GLY) demonstrated the most significant therapeutic benefit in the controlled cortical impact (CCI) model of TBI, improving motor function and reducing lesion volume.
  • GLY is the only drug tested by OBTT to reduce lesion volume after CCI, highlighting its potential.
  • These findings support a model-based approach for TBI drug development, suggesting GLY's efficacy is specific to certain injury phenotypes like contusion, advancing precision medicine in TBI.